MARKET

EXAS

EXAS

Exact Sciences Corp
NASDAQ
69.06
+2.18
+3.26%
After Hours: 69.38 +0.32 +0.46% 18:29 03/28 EDT
OPEN
67.18
PREV CLOSE
66.88
HIGH
71.62
LOW
67.18
VOLUME
5.47M
TURNOVER
0
52 WEEK HIGH
100.77
52 WEEK LOW
56.05
MARKET CAP
12.54B
P/E (TTM)
-60.9371
1D
5D
1M
3M
1Y
5Y
Noteworthy Thursday Option Activity: ITCI, FSLR, EXAS
NASDAQ · 19h ago
Exact Sciences gains after data for novel cancer screening test
Exact Sciences gains after data for novel cancer screening test. Oncoguard Esophagus test is a non-endoscopic method to detect esophageal adenocarcinoma. Exact Sciences has partnered with Mayo Clinic to develop the test.
Seeking Alpha · 19h ago
REX American Resources Reports Upbeat Earnings, Joins Avalo Therapeutics, RH And Other Big Stocks Moving Higher On Thursday
REX American Resources Corporation shares jumped 23.2% to $54.15 after upbeat quarterly earnings. Avalo Therapeutics, Inc. Shares gained 430% in Thursday's session. The S&P 500 gained around 0.1% on Thursday. RH posted weaker-than-expected results for its fourth quarter.
Benzinga · 23h ago
5 Best Healthcare Stocks to Buy in March 2024, According to Analysts
TipRanks · 2d ago
Exact Sciences Named 2024 Gallup Exceptional Workplace Award Winner
Exact Sciences Corp. Has received the 2024 Gallup Exceptional Workplace Award. The award recognizes the most engaged workplace cultures in the world. Exact Sciences is a leading provider of cancer screening and diagnostic tests. The ratio of engaged employees to actively disengaged employees is 11 times higher than the global average.
Barchart · 2d ago
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
NASDAQ · 3d ago
Here's How Much You'd Have If You Invested $1000 in Exact Sciences a Decade Ago
NASDAQ · 4d ago
Weekly Report: what happened at EXAS last week (0318-0322)?
Weekly Report · 4d ago
More
About EXAS
Exact Sciences Corporation is a global advanced cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. The Company is focusing its research and development efforts on three main areas: Colorectal Cancer Screening, MCED Test Development and MRD Test Development. The Company’s products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, and OncoExTra Test. The Company’s flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.

Webull offers Exact Sciences Corp stock information, including NASDAQ: EXAS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EXAS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EXAS stock methods without spending real money on the virtual paper trading platform.